Vetoryl 120 mg Chewable Tablets for Dogs
Active ingredient: Trilostane
Form
Chewable
Species
Manufacturer
Dechra Regulatory B.V.
VMD MA No.
50406/5008
What it's used for
For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing’s disease and syndrome).
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Trilostane
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Vetoryl 120 mg Chewable Tablets for Dogs — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
hyperadrenocorticism (Cushing’s disease and syndrome).
Administer once daily, with food.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Titrate the dose according to individual response, as determined by monitoring (see
below). If a dose increase is required, use the appropriate tablet strength and tablet
part to slowly increase the once daily dose. A wide range of divisible tablet strengths
enables optimum dosing for the individual dog. Administer the lowest dose
necessary to control the clinical signs.
Ultimately, if symptoms are not adequately controlled for an entire 24 hour inter-dose
period, consider increasing the total daily dose by up to 50 % and dividing it equally
between morning and evening doses.
A small number of animals may require doses significantly in excess of 10 mg per kg
body weight per day. In these situations appropriate additional monitoring should be
implemented.
A dose adjustment may be necessary if the dog is swapped from Vetoryl hard
capsules to Vetoryl chewable tablets, or vice versa, as a strict interchangeability
between the two products cannot be assured, as some dogs may respond differently
to the change in pharmaceutical form.
Monitoring:
Samples should be taken for biochemistry (including electrolytes) and an
adrenocorticotrophic hormone (ACTH) stimulation test pre-treatment following initial
diagnosis, and then at 10 days, 4 weeks, 12 weeks, and thereafter every 3 months,
for monitoring at regular intervals, after each dose adjustment, or if swapping from
Vetoryl hard capsules to Vetoryl chewable tablets, or vice versa.
It is imperative that ACTH stimulation tests are performed 4-6 hours post-dosing to
enable accurate interpretation of results. Dosing in the morning is preferable as this
will allow your veterinary surgeon to perform monitoring tests 4-6 hours following
administration of the dose. Regular assessment of the clinical progress of the
disease should also be made at each of the above time points.
In the event of a non-stimulatory ACTH stimulation test during monitoring, treatment
should be stopped for 7 days and then re-started at a lower dose. Repeat the ACTH
stimulation test after a further 14 days. If the result is still non-stimulatory, stop
treatment until clinical signs of hyperadrenocorticism recur. Repeat the ACTH
stimulation test one month after re-starting treatment.
Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the
tablet on a flat surface, with its scored side facing up and the convex (rounded) side
facing the surface.
2 equal parts: press down with your thumbs on both sides of the tablet.
4 equal parts: press down with your thumb in the middle of the tablet.
insufficiency.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in dogs weighing less than 5 kg.
Uncommon
(1 to 10 animals / 1,000 animals treated):
Lethargy
a,b
, Anorexia
a,b
,
Vomiting
a,b
, Diarrhoea
a,b
Rare
(1 to 10 animals / 10,000 animals treated):
Hypoadrenocorticism
c
,
Hypersalivation
d
, Bloated
d
,
Ataxia
d
, Muscle tremor
d
,
Skin disorders
d
,
Renal insufficiency
e
,
Arthritis
e
,
Weakness
a,b
Very rare
(<1 animal / 10,000 animals treated, including
isolated reports):
Adrenal necrosis
f
,
Sudden death
a
associated with iatrogenic hypoadrenocorticism, particularly if monitoring is
not adequate (see section 3.9); generally reversible within a variable period
following withdrawal of treatment.
b
has been seen in dogs treated with trilostane in the absence of evidence of
hypoadrenocorticism.
c
including Acute Addisonian Crisis (collapse) (see section 3.10).
d
mild.
e
unmasked by treatment with the product due to a reduction in endogenous
corticosteroid levels.
f
may result in hypoadrenocorticism.
Corticosteroid withdrawal syndrome or hypocortisolaemia should be distinguished
from hypoadrenocorticism by evaluation of serum electrolytes.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Where there is no apparent response to treatment, the diagnosis should be re-
evaluated. Dose increases may be necessary.
Veterinarians should be aware that dogs with hyperadrenocorticism are at increased
risk of pancreatitis. This risk may not diminish following treatment with trilostane.
Special precautions for safe use in the target species:
As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the
ages of 10 – 15 years, other pathological processes are frequently present. It is
particularly important to screen cases for primary hepatic disease and renal
insufficiency as the veterinary medicinal product is contraindicated in these cases.
Subsequent close monitoring during treatment should be carried out. Particular
attention should be paid to liver enzymes, electrolytes, urea and creatinine.
The presence of diabetes mellitus and hyperadrenocorticism together requires
specific monitoring. If a dog has previously been treated with mitotane, its adrenal
function will have been reduced. Experience in the field suggests that an interval of
at least a month should elapse between cessation of mitotane and the introduction of
trilostane. Close monitoring of adrenal function is advised, as dogs may be more
susceptible to the effects of trilostane.
The veterinary medicinal product should be used with extreme caution in dogs with
pre-existing anaemia as further reductions in packed-cell volume and haemoglobin
may occur. Dogs should be monitored at regular intervals for primary hepatic
disease, renal disease, and for diabetes mellitus.
The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out
of reach of animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Trilostane may decrease testosterone synthesis and has anti-progesterone
properties. Women who are pregnant or are intending to become pregnant should
avoid handling the veterinary medicinal product.
Wash hands after use. People with known hypersensitivity to trilostane or any of the
excipients should avoid contact with the veterinary medicinal product.
To prevent children from having access to the tablets, used blister packs should be
stored in the original carton out of sight and reach of children.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or label to the physician. Accidental ingestion may cause adverse
effects including vomiting and diarrhoea.
Special precautions for the protection of the environment:
Not applicable.
studied. Given that hyperadrenocorticism tends to occur in older dogs, many will be
receiving concurrent medication. In clinical studies, no interactions were observed.
The risk of hyperkalaemia developing should be considered if trilostane is used in
conjunction with potassium-sparing diuretics or angiotensin converting enzyme
(ACE) inhibitors. The concurrent use of such drugs should be subject to a risk-
benefit analysis by the veterinary surgeon, as death (including sudden death) has
been reported in dogs when treated concurrently with trilostane and an ACE
inhibitor.
Tablet fractions should be stored in the original blister and outer carton and should
be used at the next administration.
4.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Other Products Containing Trilostane
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Trilocur 10 mg/ml Oral Suspension for Dogs
POM-VEmdoka bvba
Trilocur 50 mg/ml Oral Suspension for Dogs
POM-VEmdoka bvba
Trilocur 50 mg/ml Oral Suspension for Dogs
POM-VEmdoka
Trilorale 10 mg/ml Oral suspension for Dogs
POM-VAxience
Trilorale 50 mg/ml Oral Suspension for Dogs
POM-VAxience
Trilorale 50 mg/ml Oral Suspension for Dogs
POM-VAxience
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
VetBox Flea & Worm Protection for Dogs
Vet-founded monthly parasite subscription. Flea, tick and worm protection delivered to your door. Founded by Dr Will Woodley, protecting 30,000+ pets.
We may earn a small commission if you purchase through these links, at no extra cost to you.
Related Medications
ACEGON 50 micrograms/ml Solution for Injection for Cattle
POM-VGonadorelin
Altresyn 4 mg/ml Oral Solution for Pigs
POM-VAltrenogest
Altresyn 4 mg/ml Oral Solution for Pigs
POM-VAltrenogest
Busol - 0.004 mg/ml Solution for Injection for Cattle, Horses, Rabbits
POM-VBuserelin
Caninsulin 40 IU/ml Suspension for Injection
POM-VInsulin
Chorulon 1500 IU Powder and Solvent for Solution for Injection
POM-VChorionic Gonadotrophin
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.